Top
GettyImages-182157308-correctedligtscreenWithchestxxray.jpg
GettyImages-182157308-correctedligtscreenWithchestxxray.jpg

Addressing Critical Infectious Disease Threats with Targeted Monoclonal Antibody Immunotherapies


 

 

SCROLL DOWN

Addressing Critical Infectious Disease Threats with Targeted Monoclonal Antibody Immunotherapies


 

 

Our current monoclonal antibody programs address specific bacterial and viral pathogens. Our Phase 2 program, ASN100, selectively targets Staphylococcus aureus virulence rather than directly killing the bacteria, potentially allowing Arsanis to combat critical infections without contributing to antibiotic resistance or damaging the patient’s microbiome.


featured news